{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:20:36Z","timestamp":1791552036368,"version":"4.3.4"},"reference-count":108,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>The burden of nonalcoholic fatty liver disease (NAFLD) is rising globally. Cardiovascular disease is the leading cause of death in patients with NAFLD. Nearly half of individuals with NAFLD have coronary heart disease, and more than a third have carotid artery atherosclerosis. Individuals with NAFLD are at a substantially higher risk of fatal and nonfatal cardiovascular events. NAFLD and cardiovascular disease share multiple common disease mechanisms, such as systemic inflammation, insulin resistance, genetic risk variants, and gut microbial dysbiosis. In this review, we discuss the epidemiology of cardiovascular disease in NAFLD, and highlight common risk factors. In addition, we examine recent advances evaluating the shared disease mechanisms between NAFLD and cardiovascular disease. In conclusion, multidisciplinary collaborations are required to further our understanding of the complex relationship between NAFLD and cardiovascular disease and potentially identify therapeutic targets.<\/jats:p>","DOI":"10.1055\/a-1930-6658","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T20:53:20Z","timestamp":1661460800000},"page":"455-464","source":"Crossref","is-referenced-by-count":41,"title":["Shared Mechanisms between Cardiovascular Disease and NAFLD"],"prefix":"10.1055","volume":"42","author":[{"given":"Daniel Q.","family":"Huang","sequence":"additional","affiliation":[{"name":"NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, San Diego, California"},{"name":"Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Downes","sequence":"additional","affiliation":[{"name":"Gene Expression Laboratory, Salk Institute for Biological Studies, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Evans","sequence":"additional","affiliation":[{"name":"Gene Expression Laboratory, Salk Institute for Biological Studies, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University California San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Glass","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, University of California San Diego, San Diego, California"},{"name":"Department of Medicine, University of California San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[{"name":"NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, San Diego, California"},{"name":"Division of Epidemiology, Department of Family Medicine and Public Health, University of California at San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Z M Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"21","key":"ref2","first-page":"01280-5","article-title":"Global NAFLD prevalence - a systematic review and meta-analysis","volume":"S1542-3565","author":"M H Le","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"R Loomba","year":"2021","journal-title":"Cell"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"R Loomba","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"D Q Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"23","author":"D JH Tan","year":"2022","journal-title":"Lancet Oncol"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/apt.16844","article-title":"Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: a prospective study","volume":"55","author":"D Q Huang","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","article-title":"Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer","volume":"34","author":"D Q Huang","year":"2022","journal-title":"Cell Metab"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"C Estes","year":"2018","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic fatty liver disease: pathogenesis and disease spectrum","volume":"11","author":"T Hardy","year":"2016","journal-title":"Annu Rev Pathol"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11892-021-01383-7","article-title":"The relationship between type 2 diabetes, NAFLD, and cardiovascular risk","volume":"21","author":"C Caussy","year":"2021","journal-title":"Curr Diab Rep"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"G Targher","year":"2016","journal-title":"J Hepatol"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/gutjnl-2016-311854","article-title":"Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study","volume":"66","author":"D H Sinn","year":"2017","journal-title":"Gut"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"L A Adams","year":"2017","journal-title":"Gut"},{"issue":"08","key":"ref15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.metabol.2015.09.017","article-title":"Non-alcoholic fatty liver disease and risk of cardiovascular disease","volume":"65","author":"A Lonardo","year":"2016","journal-title":"Metabolism"},{"issue":"14","key":"ref16","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"G Targher","year":"2010","journal-title":"N Engl J Med"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"L A Adams","year":"2005","journal-title":"Gastroenterology"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"M Ekstedt","year":"2006","journal-title":"Hepatology"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep4.1054","article-title":"Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease","volume":"1","author":"Z M Younossi","year":"2017","journal-title":"Hepatol Commun"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2016.02.023","article-title":"Fatty liver is an independent predictor of early carotid atherosclerosis","volume":"65","author":"R Pais","year":"2016","journal-title":"J Hepatol"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1148\/radiol.14140933","article-title":"High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial","volume":"274","author":"S B Puchner","year":"2015","journal-title":"Radiology"},{"issue":"09","key":"ref22","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/apt.16324","article-title":"Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease","volume":"53","author":"J G Park","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.atherosclerosis.2014.05.962","article-title":"Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study","volume":"235","author":"L B VanWagner","year":"2014","journal-title":"Atherosclerosis"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2008.06.012","article-title":"Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review","volume":"49","author":"S Sookoian","year":"2008","journal-title":"J Hepatol"},{"issue":"07","key":"ref25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"S L Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2337\/dc06-0135","article-title":"Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease","volume":"29","author":"G Targher","year":"2006","journal-title":"Diabetes Care"},{"issue":"21","key":"ref27","first-page":"01035-1","article-title":"A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease","volume":"S1542-3565","author":"J ZK Toh","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"l5367","DOI":"10.1136\/bmj.l5367","article-title":"Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults","volume":"367","author":"M Alexander","year":"2019","journal-title":"BMJ"},{"issue":"03","key":"ref29","first-page":"483","article-title":"NAFLD increases risk of carotid atherosclerosis and ischemic stroke. An updated meta-analysis with 135,602 individuals","volume":"28","author":"A SP Tang","year":"2022","journal-title":"Korean J Hepatol"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Z Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1665-2681(19)31253-0","article-title":"Survey of health status, nutrition and geography of food selection of chronic liver disease patients","volume":"13","author":"T Leslie","year":"2014","journal-title":"Ann Hepatol"},{"issue":"08","key":"ref32","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/apt.12038","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study","volume":"36","author":"L Gerber","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"24","key":"ref33","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations","volume":"133","author":"C C Low Wang","year":"2016","journal-title":"Circulation"},{"issue":"05","key":"ref34","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/apt.15163","article-title":"Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside","volume":"49","author":"S Sookoian","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13098-020-00605-4","article-title":"The prevalence of metabolic syndrome in cardiovascular patients in Iran: a systematic review and meta-analysis","volume":"12","author":"N Salari","year":"2020","journal-title":"Diabetol Metab Syndr"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"H Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.atherosclerosis.2009.10.011","article-title":"Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease","volume":"209","author":"S Sookoian","year":"2010","journal-title":"Atherosclerosis"},{"issue":"07","key":"ref38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease","volume":"15","author":"Q M Anstee","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"05","key":"ref39","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"O Krenkel","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.20283","article-title":"Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway","volume":"40","author":"A E Feldstein","year":"2004","journal-title":"Hepatology"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/j.1572-0241.2007.01774.x","article-title":"Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis","volume":"103","author":"A Wieckowska","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1665-2681(19)30912-3","article-title":"Kinetics of the inflammatory response induced by free fatty acid accumulation in hepatocytes","volume":"13","author":"N C Ch\u00e1vez-Tapia","year":"2013","journal-title":"Ann Hepatol"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.cgh.2018.11.037","article-title":"Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the Framingham Heart Study","volume":"17","author":"Z P Fricker","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijcard.2018.01.046","article-title":"Circulating interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: results from the Multi-Ethnic Study of Atherosclerosis","volume":"259","author":"T G Simon","year":"2018","journal-title":"Int J Cardiol"},{"issue":"14","key":"ref45","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"S Kaptoge","year":"2012","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"5902947","DOI":"10.1155\/2016\/5902947","article-title":"Chemokines and heart disease: a network connecting cardiovascular biology to immune and autonomic nervous systems","volume":"2016","author":"V Dusi","year":"2016","journal-title":"Mediators Inflamm"},{"issue":"16","key":"ref47","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jacc.2019.03.024","article-title":"Intestinal microbiota in cardiovascular health and disease: JACC State-of-the-Art Review","volume":"73","author":"W HW Tang","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"P Duewell","year":"2010","journal-title":"Nature"},{"issue":"07","key":"ref49","first-page":"389","article-title":"Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities","volume":"16","author":"M B\u00e4ck","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"23","key":"ref50","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"P Libby","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref51","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jhep.2014.11.030","article-title":"Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease","volume":"62","author":"S Petta","year":"2015","journal-title":"J Hepatol"},{"issue":"06","key":"ref52","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s12072-019-09972-1","article-title":"Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis","volume":"13","author":"B Liu","year":"2019","journal-title":"Hepatol Int"},{"issue":"20","key":"ref53","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium","volume":"71","author":"M Packer","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"06","key":"ref54","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/cvr\/cvz062","article-title":"The epicardial adipose tissue and the coronary arteries: dangerous liaisons","volume":"115","author":"R Madonna","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"11","key":"ref55","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.tem.2011.07.003","article-title":"Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features","volume":"22","author":"G Iacobellis","year":"2011","journal-title":"Trends Endocrinol Metab"},{"issue":"18","key":"ref56","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJM199610313351804","article-title":"Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects","volume":"335","author":"G Perseghin","year":"1996","journal-title":"N Engl J Med"},{"issue":"31","key":"ref57","doi-asserted-by":"crossref","first-page":"12587","DOI":"10.1073\/pnas.0705408104","article-title":"The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome","volume":"104","author":"K F Petersen","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"ref58","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.2337\/db12-0206","article-title":"Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly","volume":"61","author":"C Flannery","year":"2012","journal-title":"Diabetes"},{"issue":"10","key":"ref59","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/01.CIR.93.10.1809","article-title":"Insulin sensitivity and atherosclerosis","volume":"93","author":"G Howard","year":"1996","journal-title":"Circulation"},{"issue":"12","key":"ref60","doi-asserted-by":"crossref","first-page":"e52036","DOI":"10.1371\/journal.pone.0052036","article-title":"Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis","volume":"7","author":"K B Gast","year":"2012","journal-title":"PLoS One"},{"issue":"06","key":"ref61","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2337\/db15-1552","article-title":"Insulin regulates hepatic triglyceride secretion and lipid content via signaling in the brain","volume":"65","author":"T Scherer","year":"2016","journal-title":"Diabetes"},{"issue":"03","key":"ref62","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI7535","article-title":"Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle","volume":"105","author":"K Cusi","year":"2000","journal-title":"J Clin Invest"},{"issue":"06","key":"ref63","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/CIRCINTERVENTIONS.109.876672","article-title":"Diabetes duration is associated with increased thin-cap fibroatheroma detected by intravascular ultrasound with virtual histology","volume":"2","author":"J B Lindsey","year":"2009","journal-title":"Circ Cardiovasc Interv"},{"issue":"04","key":"ref64","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1042\/CS20120413","article-title":"The vascular smooth muscle cell: a therapeutic target in Type 2 diabetes?","volume":"125","author":"K E Porter","year":"2013","journal-title":"Clin Sci (Lond)"},{"issue":"06","key":"ref65","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1210\/er.2018-00141","article-title":"Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents","volume":"40","author":"A Di Pino","year":"2019","journal-title":"Endocr Rev"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"III27","DOI":"10.1161\/01.CIR.0000131515.03336.f8","article-title":"Role of endothelial dysfunction in atherosclerosis","volume":"109","author":"J Davignon","year":"2004","journal-title":"Circulation"},{"issue":"02","key":"ref67","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.20781","article-title":"Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease","volume":"42","author":"N Villanova","year":"2005","journal-title":"Hepatology"},{"issue":"02","key":"ref68","doi-asserted-by":"crossref","first-page":"e31799","DOI":"10.1371\/journal.pone.0031799","article-title":"Decreased circulating endothelial progenitor cell levels and function in patients with nonalcoholic fatty liver disease","volume":"7","author":"C-H Chiang","year":"2012","journal-title":"PLoS One"},{"issue":"09","key":"ref69","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/j.1440-1746.2005.03891.x","article-title":"Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease","volume":"20","author":"M Gulsen","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"issue":"02","key":"ref70","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11883-006-0046-4","article-title":"Homocysteine: role and implications in atherosclerosis","volume":"8","author":"S Guthikonda","year":"2006","journal-title":"Curr Atheroscler Rep"},{"issue":"02","key":"ref71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1586\/17512433.2015.1010516","article-title":"Homocysteine and the pathogenesis of atherosclerosis","volume":"8","author":"K S McCully","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"02","key":"ref72","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.atherosclerosis.2011.05.014","article-title":"Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease","volume":"218","author":"S Sookoian","year":"2011","journal-title":"Atherosclerosis"},{"issue":"04","key":"ref73","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/pr.58.4.5","article-title":"International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors","volume":"58","author":"L Michalik","year":"2006","journal-title":"Pharmacol Rev"},{"issue":"03","key":"ref74","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2217\/fca-2017-0019","article-title":"PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-\u03b2\/\u03b4 and PPAR-\u03b3","volume":"13","author":"L Han","year":"2017","journal-title":"Future Cardiol"},{"issue":"06","key":"ref75","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/hep.23927","article-title":"Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor \u03b3 coactivator 1\u03b1 promoter","volume":"52","author":"S Sookoian","year":"2010","journal-title":"Hepatology"},{"issue":"04","key":"ref76","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"S Gawrieh","year":"2021","journal-title":"Hepatology"},{"issue":"17","key":"ref77","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"S M Francque","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"ref78","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"A Nakajima","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"05","key":"ref79","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"K Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"02","key":"ref80","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cgh.2018.08.065","article-title":"Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function","volume":"17","author":"S R Sharpton","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"06","key":"ref81","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"L Miele","year":"2009","journal-title":"Hepatology"},{"issue":"05","key":"ref82","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"R Loomba","year":"2017","journal-title":"Cell Metab"},{"issue":"01","key":"ref83","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","article-title":"A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease","volume":"10","author":"C Caussy","year":"2019","journal-title":"Nat Commun"},{"issue":"01","key":"ref84","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41467-017-00900-1","article-title":"The gut microbiome in atherosclerotic cardiovascular disease","volume":"8","author":"Z Jie","year":"2017","journal-title":"Nat Commun"},{"issue":"11","key":"ref85","doi-asserted-by":"crossref","first-page":"e002699","DOI":"10.1161\/JAHA.115.002699","article-title":"Dysbiosis of gut microbiota with reduced trimethylamine-N-oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack","volume":"4","author":"J Yin","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"04","key":"ref86","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1499-3872(17)60019-5","article-title":"Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease","volume":"16","author":"F Shen","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"03","key":"ref87","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"J Boursier","year":"2016","journal-title":"Hepatology"},{"issue":"05","key":"ref88","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"J Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"07","key":"ref89","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1053\/j.gastro.2015.08.011","article-title":"Heritability of hepatic fibrosis and steatosis based on a prospective twin study","volume":"149","author":"R Loomba","year":"2015","journal-title":"Gastroenterology"},{"issue":"01","key":"ref90","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","article-title":"Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology","volume":"17","author":"M Eslam","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"03","key":"ref91","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.31113","article-title":"PNPLA3 genotype and risk of liver and all-cause mortality","volume":"71","author":"S Stender","year":"2020","journal-title":"Hepatology"},{"issue":"03","key":"ref92","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.31032","article-title":"Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the U.S. population","volume":"71","author":"A Unalp-Arida","year":"2020","journal-title":"Hepatology"},{"issue":"12","key":"ref93","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"S Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"06","key":"ref94","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/hep.29041","article-title":"The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells","volume":"65","author":"F V Bruschi","year":"2017","journal-title":"Hepatology"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hep.28475","article-title":"Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes","volume":"64","author":"M Eslam","year":"2016","journal-title":"Hepatology"},{"issue":"04","key":"ref96","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"J Kozlitina","year":"2014","journal-title":"Nat Genet"},{"issue":"12","key":"ref97","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/ng.3977","article-title":"Exome-wide association study of plasma lipids in >300,000 individuals","volume":"49","author":"D J Liu","year":"2017","journal-title":"Nat Genet"},{"issue":"06","key":"ref98","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.28142","article-title":"The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis","volume":"62","author":"C J Pirola","year":"2015","journal-title":"Hepatology"},{"issue":"04","key":"ref99","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2016.12.020","article-title":"PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery disease","volume":"152","author":"N Simons","year":"2017","journal-title":"Gastroenterology"},{"issue":"02","key":"ref100","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"P Dongiovanni","year":"2015","journal-title":"Hepatology"},{"issue":"07","key":"ref101","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/hep4.1183","article-title":"Patatin-like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events","volume":"2","author":"S R\u00fcschenbaum","year":"2018","journal-title":"Hepatol Commun"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"B A Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Z M Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"P Ramachandran","year":"2019","journal-title":"Nature"},{"issue":"11","key":"ref105","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1161\/CIRCRESAHA.120.316770","article-title":"Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics","volume":"127","author":"M AC Depuydt","year":"2020","journal-title":"Circ Res"},{"issue":"02","key":"ref106","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12072-022-10319-6","article-title":"Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis","volume":"16","author":"J N Yong","year":"2022","journal-title":"Hepatol Int"},{"issue":"04","key":"ref107","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14044","article-title":"Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis","volume":"39","author":"A Mantovani","year":"2019","journal-title":"Liver Int"},{"issue":"04","key":"ref108","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MEG.0000000000002299","article-title":"Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis","volume":"34","author":"S Ciardullo","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1930-6658.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T00:43:11Z","timestamp":1700959391000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1930-6658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":108,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2022,12,2]]},"published-print":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1930-6658","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,25]]},"published":{"date-parts":[[2022,8,25]]}}}